
Investors
Information Disclosure
-
POLL RESULTS OF ANNUAL GENERAL MEETING HELD ON 10 JUNE 20252025.06.10
-
VOLUNTARY ANNOUNCEMENT2025.06.10
-
AMENDED AND RESTATED ARTICLES OF ASSOCIATION2025.06.10
-
VOLUNTARY ANNOUNCEMENT - TQC3721 INHALATION SUSPENSION "PDE3/4 INHIBITOR" OBTAINING APPROVAL FOR PHASE III REGISTRATIONAL CLINICAL STUDY FROM CDE2025.06.09
-
VOLUNTARY ANNOUNCEMENT - DATA FROM PHASE III STUDY OF BENMELSTOBART WITH OR WITHOUT ANLOTINIB AS MAINTENANCE TREATMENT FOR NON-SMALL CELL LUNG CANCER WITHOUT PROGRESSION FOLLOWING CHEMORADIOTHERAPY PRESENTED AT 2025 ASCO ANNUAL MEETING2025.06.05
-
VOLUNTARY ANNOUNCEMENT - DATA FROM PHASE III STUDY OF BENMELSTOBART IN COMBINATION WITH ANLOTINIB AS FIRST-LINE TREATMENT FOR PD-L1 POSITIVE NON-SMALL CELL LUNG CANCER PRESENTED AT 2025 ASCO ANNUAL MEETING2025.06.03
-
MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 31 MAY 20252025.06.02
-
VOLUNTARY ANNOUNCEMENT2025.05.29